Maternales Anti-D führt zu einer verzögerten Hämolyse bei einem Neugeborenen

Zusammenfasssung

Mütterliche Antikörper, welche sich gegen fetale erythrozytäre Antigene richten, können eine Hämolytische Erkrankung des Fetus oder Neugeborenen (HDFN) verursachen. In schweren Fällen ist die HDFN mit hoher perinataler Mortalität und Langzeitdefiziten assoziiert. Maternale Antikörper werden diaplazentar übertragen, sodass diese bereits intrauterin zur Hämolyse führen. Vereinzelt treten verzögerte Hämolysen des Neugeborenen auf.

Abstract

Background Hemolytic disease of fetus and newborn (HDFN) is caused by maternal antibodies that react to fetal red blood cell antigens. HDFN is associated with perinatal mortality and long-term neurological deficits in severe cases. Alloantibodies will lead to hemolysis of fetal erythroid cells and cause fetal and neonatal anemia. Rhesus D (Rh D) antigen is a frequent cause of HDFN. In most cases, the maternal alloantibody transported across the placenta causes hemolysis in utero. Only a few cases of delayed-onset hemolysis in the newborn have been reported yet.

Case report A mother with a high anti-D titer gave birth to a newborn with a normal postnatal hemoglobin level. The newborn's direct antiglobulin test (DAT) was positive for immunoglobulin G, with an anti-D titer of 4096 in elution. After 2 days of phototherapy for mild icterus, the newborn was discharged with a hemoglobin of 17.4 g/dl and without any complications. Twenty days after birth, the newborn was admitted to the children’s hospital because of paleness. On admission, hemoglobin was 5.6 g/dl and total bilirubin was 2.6 mg/dl. No infection was found. DAT was positive with an anti-D titer of 4096 in elution. After red blood cell transfusion, hemoglobin increased and the newborn was discharged. On day 34 postpartum, hemoglobin was 8.1 mg/dl and anti-D titer was 1024 in elution. No further transfusion was indicated. The newborn was discharged in a good physical condition for regular follow-up by the resident pediatrician.

Conclusion Implementation of Rh D antibody prophylaxis in Rh D-negative non-immunized women has led to a marked reduction in the incidence of Rh D alloimmunization and eventually HDFN. However, maternal Rh-D antibodies can induce delayed HDFN, even in the absence of hemolysis signs at birth. Increased vigilance and frequent monitoring of newborns with maternal alloantibodies are of great importance to prevent complications of a delayed HDFN.

Schlüsselwörter

Neonatale Anämie - Hämolytische Erkrankung - Maternale Antikörper - verzögerte Hämolyse - neonatale Blutgruppe

Key words

newborn anemia - hemolytic disease - maternal antibodies - delayed hemolysis - newborn’s blood group

Publication History

Article published online:
11 May 2023

• Literatur

• 1 Haas de M, Thurik FF, Koelewijn JM. et al. Haemolytic disease of the fetus and newborn. Vox Sang 2015; 109: 99-113 DOI: 10.1111/vox.12265.
• 2 Ree IMC, Smits-Wintjens VEHJ, van der Bom JG. et al. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol 2017; 10: 607-616 DOI: 10.1080/17474086.2017.1331124.
• 3 Prefumo F, Fichera A, Fratelli N. et al. Fetal anemia: Diagnosis and management. Best Pract Res Clin Obstet Gynaecol 2019; 58: 2-14 DOI: 10.1016/j.bpobgyn.2019.01.001.
• 4 Elhence P, Sachan D, Verma A. et al. Late onset neonatal anaemia due to maternal anti-Kp(b) induced haemolytic disease of the newborn. Transfus Apher Sci 2012; 47: 247-250 DOI: 10.1016/j.transci.2012.09.001.
• 5 Zwiers C, van Kamp I, Oepkes D. et al. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn – review on current management and outcome. Expert Rev Hematol 2017; 10: 337-344 DOI: 10.1080/17474086.2017.1305265.
• 6 Vlachodimitropoulou E, Garbowski M, Anne Solomon S. et al. Outcome predictors for maternal red blood cell alloimmunisation with anti-K and anti-D managed with intrauterine blood transfusion. Br J Haematol 2022; 196: 1096-1104 DOI: 10.1111/bjh.17956.
• 7 Tiblad E, Kublickas M, Ajne G. et al. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther 2011; 30: 266-273 DOI: 10.1159/000328683.
• 8 Koelewijn JM, Haas de M, Vrijkotte TGM. et al. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008; 48: 1721-1729 DOI: 10.1111/j.1537-2995.2008.01742.x.
• 9 Rasalam JE, Kumar S, Amalraj P. et al. Do red cell alloantibodies continue to challenge breast fed babies?. Transfus Med 2020; 30: 281-286 DOI: 10.1111/tme.12672.